Saniona share spikes on strong diabetes data
Nordic biotech Saniona has presented solid topline results from a phase II trial with a diabetes drug, causing its share price to swell by nearly 20 percent.
BY LONNI LYNGE
The Denmark-based, Sweden-listed biotech company Saniona has shown topline data from a phase IIa trial with lead candidate Tesomet, it said in a press release Tuesday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Saniona readies phase II trial in diabetes
For abonnenter
